Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

被引：53
|
作者：
Birtle, Alison Jane
Chester, John David
Jones, Robert Jones
Johnson, Mark
Hill, Michaela
Bryan, Richard T.
Catto, James
Donovan, Jenny
French, Ann
Harris, Chris
Keeley, Francis
Kockelbergh, Roger
Powles, Thomas
Todd, Rachel
Tregellas, Lucy
Wilson, Caroline
Winterbottom, Andrew
Lewis, Rebecca
Hall, Emma
机构：
[1] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
[2] Cardiff Univ, Cardiff, Wales
[3] Univ Glasgow, Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] Newcastle Tyne Hosp NHS Trust, Newcastle, NSW, Australia
[5] Inst Canc Res, Clin Trials & Stat Unit, London, England
[6] Univ Birmingham, Birmingham, England
[7] Univ Sheffield, Sheffield, S Yorkshire, England
[8] Univ Bristol, Bristol, England
[9] Southend Univ Hosp NHS Fdn Trust, Southend On Sea, England
[10] Consumer Representat, London, England
[11] N Bristol NHS Trust, Bristol, England
[12] Univ Hosp Leicester, Leicester, Leics, England
[13] Barts Hlth NHS Trust St Bartholomews Hosp, London, England
[14] Inst Canc Res, Clin Trials & Stat Unit, London, England
[15] Inst Canc Res, Clin Trials & Stat Unit, Sutton, Surrey, England
[16] Fight Bladder Canc, Chinnor, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.407
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
407
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial
    Liu, Fangqi
    Tong, Tong
    Huang, Dan
    Yuan, Weitang
    Li, Dechuan
    Lin, Jianjiang
    Cai, Sanjun
    Xu, Ye
    Chen, Wenbin
    Sun, Yueming
    Zhuang, Jing
    BMJ OPEN, 2019, 9 (01):
  • [22] ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
    Eade, Alyssa V.
    Friedman, Lindsay R.
    Larrain, Carolina
    Rainey, Ashley
    Hernandez, Jonathan M.
    Chawla, Akhil
    Ferrone, Cristina R.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (10) : 6373 - 6374
  • [23] TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
    Trevor Leong
    B Mark Smithers
    Michael Michael
    Val Gebski
    Alex Boussioutas
    Danielle Miller
    John Simes
    John Zalcberg
    Karin Haustermans
    Florian Lordick
    Christoph Schuhmacher
    Carol Swallow
    Gail Darling
    Rebecca Wong
    BMC Cancer, 15
  • [24] TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
    Leong, Trevor
    Smithers, B. Mark
    Michael, Michael
    Gebski, Val
    Boussioutas, Alex
    Miller, Danielle
    Simes, John
    Zalcberg, John
    Haustermans, Karin
    Lordick, Florian
    Schuhmacher, Christoph
    Swallow, Carol
    Darling, Gail
    Wong, Rebecca
    BMC CANCER, 2015, 15
  • [25] INTERIM RESULTS FROM A PHASE 1B CLINICAL TRIAL EVALUATING TOLERABILITY AND ACTIVITY OF FGFR INHIBITION IN LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
    Matin, Surena
    Adibi, Mehrad
    Shah, Amishi
    Alhalabi, Omar
    Corn, Paul
    Guo, Charles
    Amirtharaj, Rhenita
    Lozano, Marisa
    Xiao, Lianchun
    Pal, Sumanta
    Campbell, Matthew
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1039 - E1040
  • [26] A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III)
    Miyamoto, Kenichi
    Ito, Akihiro
    Wakabayashi, Masashi
    Eba, Junko
    Arai, Yoichi
    Nishiyama, Hiroyuki
    Sugimoto, Mikio
    Yamashita, Ryo
    Kakehi, Yoshiyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (01) : 94 - 97
  • [27] Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77 A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma
    Singla, Nirmish
    Margulis, Vitaly
    EUROPEAN UROLOGY, 2021, 79 (01) : E28 - E28
  • [28] Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results of a phase II study
    Bi, X.
    Shou, J.
    Zhou, A.
    Zhang, W.
    Cao, C.
    Lu, L.
    Wen, L.
    Guan, Y.
    Shi, H.
    Xiao, Z.
    Jiang, Z.
    Sun, Y.
    Zheng, S.
    Zhang, J.
    EUROPEAN UROLOGY, 2022, 81 : S469 - S469
  • [29] Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC).
    Huang, Jiwei
    Cai, Xinyun
    Ng, Cheoklong
    Luo, Yuansheng
    Wang, Zaoyu
    Kong, Wen
    Zhang, Jin
    Chen, Yonghui
    Wu, Guangyu
    Chen, Haige
    Xue, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
    Powles, T.
    Gschwend, J. E.
    Loriot, Y.
    Bellmunt, J.
    Geczi, L.
    Vulsteke, C.
    Abdelsalam, M.
    Gafanov, R.
    Bae, W. K.
    Revesz, J.
    Yamamoto, Y.
    Anido, U.
    Su, W-P.
    Fleming, M.
    Markus, M.
    Feng, D.
    Poehlein, C.
    Alva, A.
    ANNALS OF ONCOLOGY, 2017, 28
12345